Genentech adds three discovery partnerships to build out pipeline

Through a trio of deals with Convelo, Skyhawk and Sosei Heptares announced Tuesday, Genentech is adding programs that could refresh its early stage neurology pipeline, as well as its oncology and other early R&D.

Global Head of Partnering James Sabry told BioCentury in March that the future of Roche (SIX:ROG; OTCQX:RHHBY) will be "a broad swath of products across many modalities and many indications." This could mean moving deeper into new areas where Roche has had some success, such as multiple sclerosis; it launched its first drug for MS in 2017 (see "Roche Broadens its BD Scope")...